MANAGEMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN RHEUMATOID ARTHRITIS; THE EXAMPLE OF THE “RIC NORD DE FRANCE” COHORT

J. Corli1, G. Baudens2, R. M. Fipio1, B. Cortel1, on behalf of RIC-Nord de France.
1Rheumatology, CHRU Lille, Lille; 2Rheumatology, Valenciennes, Valenciennes, France

Background: Glucocorticoid-induced osteoporosis (GIOP) is the most common cause of secondary osteoporosis. Patients followed for Rheumatoid Arthritis (RA) are particularly exposed to OP and have a greater risk of fracture, which must be prevented. The newest French guidelines for GIOP management were published in 2014 and it is not known yet how they are applied in real life.

Objectives: The objective of our study was to investigate the treatment of glucocorticoid-induced osteoporosis in the Rhumatismes Informatiques Chroniques – Nord de France (formerly known as RIC-NPC) network in 2016 for patients with rheumatoid arthritis (RA).

Methods: In this observational study, the patients studied were followed in the RIC network for RA from 2004 until June 2016, had at least one bone mineral density (BMD) assessment and glucocorticoid therapy during follow-up. Demographic characteristics of patients, BMD results, fractures and treatments implemented were collected from network data completed during consultations by practitioners.

Results: 647 patients were enrolled, including 511 women (79%). The average age of patients was 65.5 years (SD=12) with a mean BASDAI of 3.91 (SD=1.44), mean dose of steroid of 7.6 mg (SD=6.6) and a mean duration of treatment of 49 months (SD=53.7). The average T-score at the first BMD assessment was −0.99 at the spine and −1.03 at the total hip. 298 patients received an anti-osteoporotic treatment (46%). Treated patients were older (p<0.0001), with lower weight (p=0.0001) and had a lower T-score at both the spine and the total hip (p<0.0001 for both sites). They most often underwent a prior fracture (p<0.0001), and an initial T-score less than −1.5 SD (p=0.0001).

Conclusions: Our study has the advantage of reflecting the management of GIOP in a ‘real life’ cohort. Almost half of our patients followed for RA who received corticosteroids had received treatment. According to French guidelines the number of patients requiring an anti-osteoporotic treatment should be higher.

REFERENCES:

Disclosure of Interest: J. Corli Grant/research support from: Amgen, G. Baudens Grant/research support from: Amgen, R.-M. Fipio; None declared, B. Cortel Grant/research support from: Amgen

DOI: 10.1136/annrheumdis-2018-eular.1314

USEFULNESS OF DOPPLER ULTRASOUND EXAMINATIONS FOR DETECTING DEEP VENOUS THROMBOSIS DURING THE PERIOPERATIVE PERIOD IN PATIENTS WITH OSTEOPOROTIC FRACTURES OF THE PROXIMAL FEMUR

K. Nakaseko, N. Mayumi. Department of Orthopaedic Surgery and Rheumatology, KUWANA CITY MEDICAL CENTER, Kuwana Me, Japan

Background: Deep venous thrombosis (DVT) can lead to a venous thromboembolism and increase the risk of a pulmonary thromboembolism (PE). PE is one of the most common causes of death in hospitalised surgical patients.

Although there have been some prospective studies regarding the prevalence of DVT on Doppler ultrasound examinations of the lower extremities, there have not been any prospective studies in which three consecutive Doppler ultrasound examinations were performed to detect DVT during the perioperative period. The purpose of the present study was to prospectively evaluate the occurrence of DVT in patients with osteoporotic fractures of the proximal femur, based on the results of examinations involving three consecutive ultrasound scans. In addition, the usefulness of the d-dimer level as a predictor of DVT was investigated.

Objectives: This study was a single-centre prospective study. One hundred-five patients (18 males and 87 females) between the ages of 46 and 97 years with osteoporotic fractures of the proximal femur were enrolled. All patients were asymptomatic in terms of their clinical DVT findings.

Methods: Three Doppler ultrasound examinations of the lower extremities were conducted in each case: on admission, one day before surgery, and one week after surgery. The period from admission to surgery ranged from 2 to 8 days (mean: 5.4 days). The d-dimer level was measured at one week after surgery and its relationship with the presence/absence of DVT was evaluated by calculating sensitivity, specificity, positive predictive, and negative predictive values.

Results: DVT was detected in 20 patients (2 patients on admission, 9 patients one day before surgery, and 9 patients one week after surgery). The overall prevalence of DVT in the perioperative period was 19.0% (20/105). As for the characteristics of the patients that did and did not develop DVT, there were no significant differences between the two groups. When the d-dimer cut-off level was set at 4.3 µg/ml, the sensitivity and negative predictive value reached 100%, while the specificity was 16.5%, and the positive predictive value was 22.0%. A receiver operating characteristic (ROC) curve was drawn, and the optimal d-dimer cut-off level was examined. The ROC curve was closest to the upper left corner when the d-dimer cut-off level was 12.2 µg/mL. At that point, the sensitivity, specificity, positive predictive value, and negative predictive value were 55.0%, 69.4%, 28.9%, and 86.8%, respectively.
Conclusions: In this prospective study, DVT was detected in 2 patients on admission, 9 patients one day before surgery, and 9 patients one week after surgery. As DVT can occur at any moment, performing repeated Doppler ultrasound examinations in the perioperative period is useful for quickly detecting DVT, which can cause PE. As for the d-dimer level, its sensitivity and negative predictive value reached 100% at a cut-off level of 4.3 μg/ml. Therefore, d-dimer assays could be a useful screening tool for DVT and might be a suitable substitute for Doppler ultrasound examinations.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.1314

AB1004 OSTEOPOROSIS SCREENING IN A TERTIARY RHEUMATOID ARTHRITIS CLINIC. WHO’S SCREENING NOW?

L. Ku¹, T. Kovitwanichkanont¹,², D. Wang², N. Walpola³, S. Raghunath¹,², S. Pignataro¹, S. Morton¹, M. Leech¹,³.
¹Rheumatology, Monash Health, Melbourne; ²Sydney School of Public Health, University of Sydney, Sydney; ³Department of Medicine, Monash University, Melbourne, Australia

Background: Osteoporosis is a complication of rheumatoid arthritis (RA) due to inflammatory disease and treatment with glucocorticoids. Screening and management of osteoporosis (OP) is shared amongst General Practitioners (GP) together with subspecialists including rheumatologists.

Objectives: To assess the adequacy of osteoporosis screening in a tertiary RA clinic in Melbourne, and to determine where most screening is occurring.

Methods: A cross-sectional study of patients at a tertiary RA clinic was undertaken. Osteoporosis screening, therapy and related factors were evaluated. This was compared to best practice screening ACR/GIOP guidelines.

Results: 116 RA patients, 66% female (median age 58 years) were included. OP screening occurred in 61.2% of patients with 40.5% and 20.7% performed by their rheumatologist and by the GPs respectively. The remainder 38.8% of patients recalled no recent screening.

36.2% of patients were taking prednisolone, while 74% reported prior exposure. 58.6% of patients had prednisolone for over 3 months. Calcium or vitamin D supplementation was noted in 62% of the population. 21.6% reported a history of minimal trauma fracture and alarmingly only 10% reported currently taking anti-resorptive therapy.

47% of patients had a DEXA scan performed within the last 3 years. Of the 53% that did not have a recent DEXA scan, three quarters had indications for osteoporosis screening based on the 2010 ACR/GIOP guidelines. 35 patients had indications based on age, 11 patients based on glucocorticoid exposure and 1 patient based on history of minimal trauma fracture.

Disclosure of Interest: None declared


AB1005 RELATIONSHIP BETWEEN AUTOIMMUNITY AND OSTEOPOROSIS IN RHEUMATOID ARTHRITIS

M.C. Carnisco Cubero¹, S.M. Rojas Herrera², J. Malave Calzada², P. Pérez David², I. Braña Abascal², E. Chamizo Carmona², ¹Rheumatology, CHU de Badajoz, Badajoz; ²Rheumatology, Hospital de Mérida, Mérida, Spain

Background: Osteoporosis (OP) is more prevalent in patients with rheumatoid arthritis (RA) than in the general population. Positive anti-citrullinated peptide antibody (ACPA) has been related with juxta-articular OP, but their relationship with systemic OP in RA is controversial.

Objectives: To determine if RA autoantibodies (FR and ACPA) are associated with bone mineral density (BMD) in a cohort of patients with established RA diagnosed following the ACR 1987 criteria.

Methods: Observational study. We analysed the relationship between RF and/or ACPA with the DXA BMD values of the femoral neck (CNF) and lumbar spine (LS) (GE LUNAR Prodigy). We performed the analysis using logistic regression, bivariate and multivariate models, and correlation models. The control variables were sex, body mass, age, duration of RA, prednisone and vitamin D.

Results: We included 294 patients with RA who had all the tests, with a mean age of 63.4 (±10.9) years and duration of RA of 9.8 (±7.9) years. There were 229 (77.9%) women, 229 (77.9%) positive-RF, 196 (66.7%) positive-ACPA, 109 (37.1%) deficient in 25-OH cholecalciferol (<20 ng/ml) and 59 (20.1) smoker patients. They received corticosteroids at low doses 207 (70.4%) and suffered some bone fracture 42 (14.3%) patients. In the BMD, 226 (76.9%) patients had a DEXA scan performed within the last 3 years. Of the 53% that did not have a recent DEXA scan, three quarters had indications for osteoporosis screening based on the 2010 ACR/GIOP guidelines. 35 patients had indications based on age, 11 patients based on glucocorticoid exposure and 1 patient based on history of minimal trauma fracture.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.1314

Figure 1

Conclusions: One third of at-risk patients in this sub-cohort are not screened for osteoporosis. More patients are currently screened for osteoporosis by their rheumatologist than their GPs. Underscreening and treatment of osteoporosis in this clinic could be addressed by clearer GP-rheumatologist shared treatment model.

REFERENCES: